{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:20:28Z","timestamp":1792189228988,"version":"4.4.0"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The bacterial cell division protein FtsZ is an attractive target for small-molecule antibacterial drug discovery. Derivatives of 3-methoxybenzamide, including compound PC190723, have been reported to be potent and selective antistaphylococcal agents which exert their effects through the disruption of intracellular FtsZ function. Here, we report the further optimization of 3-methoxybenzamide derivatives towards a drug candidate. The\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            characterization of a more advanced lead compound, designated compound 1, is described. Compound 1 was potently antibacterial, with an average MIC of 0.12 \u03bcg\/ml against all staphylococcal species, including methicillin- and multidrug-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus epidermidis<\/jats:named-content>\n            . Compound 1 inhibited an\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            strain carrying the G196A mutation in FtsZ, which confers resistance to PC190723. Like PC190723, compound 1 acted on whole bacterial cells by blocking cytokinesis. No interactions between compound 1 and a diverse panel of antibiotics were measured in checkerboard experiments. Compound 1 displayed suitable\n            <jats:italic>in vitro<\/jats:italic>\n            pharmaceutical properties and a favorable\n            <jats:italic>in vivo<\/jats:italic>\n            pharmacokinetic profile following intravenous and oral administration, with a calculated bioavailability of 82.0% in mice. Compound 1 demonstrated efficacy in a murine model of systemic\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            infection and caused a significant decrease in the bacterial load in the thigh infection model. A greater reduction in the number of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            cells recovered from infected thighs, equivalent to 3.68 log units, than in those recovered from controls was achieved using a succinate prodrug of compound 1, which was designated compound 2. In summary, optimized derivatives of 3-methoxybenzamide may yield a first-in-class FtsZ inhibitor for the treatment of antibiotic-resistant staphylococcal infections.\n          <\/jats:p>","DOI":"10.1128\/aac.01580-12","type":"journal-article","created":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:17:28Z","timestamp":1351729048000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":91,"title":["An Improved Small-Molecule Inhibitor of FtsZ with Superior\n            <i>In Vitro<\/i>\n            Potency, Drug-Like Properties, and\n            <i>In Vivo<\/i>\n            Efficacy"],"prefix":"10.1128","volume":"57","author":[{"given":"Neil R.","family":"Stokes","sequence":"first","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Baker","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Berry","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Collins","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd G.","family":"Czaplewski","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Logan","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Macdonald","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"MacLeod","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Peasley","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Biota Scientific Management Pty. Ltd., Notting Hill, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Nayal","sequence":"additional","affiliation":[{"name":"Jubilant Chemsys Ltd., Noida, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Yadav","sequence":"additional","affiliation":[{"name":"Jubilant Chemsys Ltd., Noida, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Jubilant Chemsys Ltd., Noida, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Haydon","sequence":"additional","affiliation":[{"name":"Biota Europe Ltd., Begbroke Science Park, Oxfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews.","author":"Infectious Diseases Society of America","year":"2004","unstructured":"Infectious Diseases Society of America. 2004. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Infectious Diseases Society of America, Alexandria, VA."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/524891"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1176667"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/533452"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2011.08.002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2201"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"AwasthiD\nKumarK\nOjimaI. 2011. Therapeutic potential of FtsZ inhibition: a patent perspective. Expert Opin. Ther. Patents 21:657\u2013679.","DOI":"10.1517\/13543776.2011.568483"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-1400-1_30"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2510"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200156"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/cb2003626"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-006-0586-0"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2198"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.67.1.52-65.2003"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.5.3.447"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.173.11.3500-3506.1991"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03719.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.16.1.89"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/34472"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/34465"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404439101"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506741200"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307625200"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi047297o"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2006.11.015"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.07.031"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1039\/B312016C"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2006.07.050"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1159961"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2011.07559.x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.094722"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003592"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.11.021"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9016366"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.181.4.1348-1351.1999"},{"key":"e_1_3_2_38_2","volume-title":"CLSI document M7-A7.","author":"Clinical and Laboratory Standards Institute","year":"2006","unstructured":"Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"7"},{"key":"e_1_3_2_39_2","first-page":"365","volume-title":"Antibiotics in laboratory medicine.","author":"Pillai SK","year":"2005","unstructured":"PillaiSK MoelleringRCJr EliopoulosGM. 2005. Antimicrobial combinations, p 365\u2013440. In LorianV (ed), Antibiotics in laboratory medicine. Lippincott Williams & Wilkins, Philadelphia, PA."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg301"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm191"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.06.029"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2006.tb03851.x"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1021\/ol052269z"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00030-10"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.13.8.1045"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(99)00005-3"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01580-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01580-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:30:21Z","timestamp":1645482621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01580-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1128\/AAC.01580-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01580-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"2012-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}